Vitiligo Treatment Market By Drug Class Type, By Type, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market

CHAPTER 4: VITILIGO TREATMENT MARKET, BY DRUG CLASS TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Corticosteroids
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.2.4 Corticosteroids Vitiligo Treatment Market by Route of Administration
4.2.4.1 Topical Route Market size and forecast, by region
4.2.4.2 Oral and Systemic Route Market size and forecast, by region
4.3 Calcineurin Inhibitor
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Others
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country

CHAPTER 5: VITILIGO TREATMENT MARKET, BY TYPE
5.1 Overview
5.1.1 Market size and forecast
5.2 Segmental
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Non Segmental
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country

CHAPTER 6: VITILIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital Pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Drug Stores and Retail Pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Online Providers
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country

CHAPTER 7: VITILIGO TREATMENT MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Drug Class Type
7.2.2.1 North America Corticosteroids Vitiligo Treatment Market by Route of Administration
7.2.3 North America Market size and forecast, by Type
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.5 North America Market size and forecast, by country
7.2.5.1 U. S.
7.2.5.1.1 Market size and forecast, by Drug Class Type
7.2.5.1.2 Market size and forecast, by Type
7.2.5.1.3 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Drug Class Type
7.2.5.2.2 Market size and forecast, by Type
7.2.5.2.3 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Drug Class Type
7.2.5.3.2 Market size and forecast, by Type
7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Drug Class Type
7.3.2.1 Europe Corticosteroids Vitiligo Treatment Market by Route of Administration
7.3.3 Europe Market size and forecast, by Type
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Drug Class Type
7.3.5.1.2 Market size and forecast, by Type
7.3.5.1.3 Market size and forecast, by Distribution Channel
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Drug Class Type
7.3.5.2.2 Market size and forecast, by Type
7.3.5.2.3 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Drug Class Type
7.3.5.3.2 Market size and forecast, by Type
7.3.5.3.3 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Drug Class Type
7.3.5.4.2 Market size and forecast, by Type
7.3.5.4.3 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Drug Class Type
7.3.5.5.2 Market size and forecast, by Type
7.3.5.5.3 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Drug Class Type
7.3.5.6.2 Market size and forecast, by Type
7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Drug Class Type
7.4.2.1 Asia-Pacific Corticosteroids Vitiligo Treatment Market by Route of Administration
7.4.3 Asia-Pacific Market size and forecast, by Type
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Drug Class Type
7.4.5.1.2 Market size and forecast, by Type
7.4.5.1.3 Market size and forecast, by Distribution Channel
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Drug Class Type
7.4.5.2.2 Market size and forecast, by Type
7.4.5.2.3 Market size and forecast, by Distribution Channel
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Drug Class Type
7.4.5.3.2 Market size and forecast, by Type
7.4.5.3.3 Market size and forecast, by Distribution Channel
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Drug Class Type
7.4.5.4.2 Market size and forecast, by Type
7.4.5.4.3 Market size and forecast, by Distribution Channel
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Drug Class Type
7.4.5.5.2 Market size and forecast, by Type
7.4.5.5.3 Market size and forecast, by Distribution Channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Drug Class Type
7.4.5.6.2 Market size and forecast, by Type
7.4.5.6.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Drug Class Type
7.5.2.1 LAMEA Corticosteroids Vitiligo Treatment Market by Route of Administration
7.5.3 LAMEA Market size and forecast, by Type
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Drug Class Type
7.5.5.1.2 Market size and forecast, by Type
7.5.5.1.3 Market size and forecast, by Distribution Channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Drug Class Type
7.5.5.2.2 Market size and forecast, by Type
7.5.5.2.3 Market size and forecast, by Distribution Channel
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Drug Class Type
7.5.5.3.2 Market size and forecast, by Type
7.5.5.3.3 Market size and forecast, by Distribution Channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Drug Class Type
7.5.5.4.2 Market size and forecast, by Type
7.5.5.4.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Players
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES
9.1 Arcutis Biotherapeutics
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Astellas Pharma Inc.
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Bausch Health Companies Inc.
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Belcher Pharmaceuticals, LCC
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Celgene Corporation
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 clinuvel pharmaceuticals ltd
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Dr. Reddy’s Laboratories Ltd
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Glenmark Pharmaceuticals Ltd
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Mylan N. V.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Panacea Biotec Ltd
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
9.11 Pfizer Inc.
9.11.1 Company overview
9.11.2 Company snapshot
9.11.3 Operating business segments
9.11.4 Product portfolio
9.11.5 Business performance
9.11.6 Key strategic moves and developments
9.12 Strides Pharma Science Limited
9.12.1 Company overview
9.12.2 Company snapshot
9.12.3 Operating business segments
9.12.4 Product portfolio
9.12.5 Business performance
9.12.6 Key strategic moves and developments

Executive Summary

According to this report, titled, 'Vitiligo Treatment Market,' the vitiligo treatment market size was valued at $410.54 million in 2021, and is estimated to reach $625.8 million by 2031, growing at a CAGR of 4.3% from 2022 to 2031.

Vitiligo, known as piebald skin or leukoderma, is a dermatology disorder caused due to deficiency of melanin pigment and characterized by development of white spots on the skin. This condition tends to advance over the time, with larger depigmentation spots on the skin, however in some individuals, patches can remain stable. It is an autoimmune physical disorder, sometimes transmitted genetically from parent to offspring.

The symptoms of vitiligo are patchy loss of skin color, whitening of the hair present on scalp, and loss of color from mucous membrane. Furthermore, people with vitiligo are more susceptible to get other autoimmune diseases such as Addison’s disease and hypothyroidism. The long-term effects of vitiligo are mental stress, skin cancer, iritis, and hearing loss due to loss of cochlear melanocytes.

Depending on the severity of patches, there are three types of vitiligo namely generalized or non-segmental, segmental, and mucosal. Generalized vitiligo is the most common type of vitiligo in which white patches appear all over the body. In segmental vitiligo, the white patches are restricted to one area such as hands or face.

The mucosal vitiligo affects the mucosal membrane of mouth and genital areas. Furthermore, vitiligo does not cause serious health problems however may result in physical complications such as sunburn, eye problems, and more likely to develop other autoimmune diseases. Moreover, the medicinal treatments for vitiligo are intended to restore uniform skin color, however does not cure the disease permanently.

Vitiligo treatment market trends which drive the growth of the market include, increase in prevalence of vitiligo and rise in demand for advanced & effective treatments for vitiligo conditions. For instance, according to IP Indian Journal of Clinical and Experimental Dermatology published in January 2022, India is considered to have highest prevalence of vitiligo about 8.8%. In addition, increase in healthcare spending, rise in number of clinical research and product approvals contributes towards the global market growth. For instance, Incyte Corporation a pharmaceutical company, reported positive results for phase-2 study of Ruxolitinib for the treatment of vitiligo.

However, high cost of treatments and side effects associated with medications are expected to hinder growth of the market during vitiligo treatment market forecast. For instance, long term use of topical corticosteroids can lead to skin thinning, high blood pressure, and fluid retention. Moreover, the rise in awareness regarding vitiligo in developing countries and increase in healthcare expenditure are the factors anticipated to create opportunities for market growth during the forecast period.

Depending on drug class type, the vitiligo treatment industry is fragmented into corticosteroids, calcineurin inhibitor, and others. The corticosteroid segment was the major revenue contributor in 2021, and expected to exhibit fastest growth during the forecast period, owing to rise in demand for corticosteroids as it shows significant result in non-segmental vitiligo treatment.

On the basis of type, the vitiligo treatment industry is bifurcated into segmental and non-segmental. The non-segmental segment was the has largest vitiligo treatment market share contributor in 2021, and is expected to exhibit fastest growth during the forecast period, owing to high prevalence of non-segmental vitiligo as it is the most common type of vitiligo.

On the basis of distribution channel, the market is segregated into hospital pharmacies, drug stores & retail pharmacies, and online providers. The drug stores and retail pharmacies segment dominated the market in 2021, owing to increased sale of medicines from drug stores & hospital pharmacies and increase in patients seeking treatments for vitiligo conditions.

However, online providers segment is expected to exhibit fastest growth during the vitiligo treatment market analysis, owing to rise in customers buying medicines online as it gives huge amount of discounts on medications.

Region wise, North America has the highest vitiligo treatment market share in 2021, and is expected to maintain its lead during the forecast period, owing to rise in awareness about vitiligo conditions, availability of treatments, and increase in research activities for developing novel therapies for vitiligo.

However, Asia-Pacific is expected to exhibit fastest growth during the forecast period, owing to high prevalence of vitiligo among adults and rise in initiatives taken by government of various countries to spread awareness about vitiligo. For instance, the World Vitiligo Day is observed on 25th of June every year.

KEY FINDINGS OF THE STUDY

• Based on drug class type, the corticosteroids segment dominated the vitiligo treatment market size in 2021.
• On the basis of type, non-segmental segment dominated the market in 2021.
• By distribution channel, drug stores and retail pharmacies segment dominated the market in 2021.
• Based on region, North America dominated the market in 2021 and is expected to grow at a CAGR of 3.4%.

Companies Mentioned

• Arcutis Biotherapeutics
• Astellas Pharma Inc.
• Bausch Health Companies Inc.
• Belcher Pharmaceuticals, Lcc
• Celgene Corporation
• Clinuvel Pharmaceuticals Ltd.
• Dr. Reddy's Laboratories Ltd.
• Glenmark Pharmaceuticals Ltd.
• Mylan N.V.
• Panacea Biotec Ltd.
• Pfizer Inc.
• Strides Pharma Science Limited

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

• Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
• Scientific and technical writings for product information and related preemptions
• Regional government and statistical databases for macro analysis
• Authentic news articles and other related releases for market evaluation
• Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.